TANGO THERAPEUTICS INC
NASDAQ: TNGX (Tango Therapeutics, Inc.)
Last update: 4 hours ago24.16
0.81 (3.47%)
| Previous Close | 23.35 |
| Volume | 456,897 |
| Price / Sales | 58.71 |
| Price / Book | 3.84 |
| 52 Weeks Range |
| Operating Margin (TTM) | -788.76% |
| Diluted EPS (TTM) | -1.20 |
| Quarterly Revenue Growth (YOY) | -16.70% |
| Total Debt/Equity (MRQ) | 22.16% |
| Current Ratio (MRQ) | 6.26 |
| Operating Cash Flow (TTM) | -135.34 M |
| Levered Free Cash Flow (TTM) | -67.25 M |
| Return on Assets (TTM) | -26.79% |
| Return on Equity (TTM) | -61.35% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Tango Therapeutics, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | -3.0 |
| Price Volatility | 2.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | -0.5 |
| Average | 0.00 |
|
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 12.59% |
| % Held by Institutions | 97.41% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Rtw Investments, Lp | 30 Jun 2026 | 13,900,620 |
| Tcg Crossover Management, Llc | 30 Jun 2026 | 9,081,201 |
| Trv Gp Iv, Llc | 30 Jun 2026 | 6,374,574 |
| Paradigm Biocapital Advisors Lp | 30 Jun 2026 | 6,357,523 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| NEWCOMB JESSICA | - | 22.33 | -8,200 | -183,106 |
| Aggregate Net Quantity | -8,200 | |||
| Aggregate Net Value ($) | -183,106 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 22.33 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| NEWCOMB JESSICA | Officer | 22 Sep 2026 | Automatic sell (-) | 8,200 | 22.33 | 183,106 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |